Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. - Montalban X; Vermersch P; Arnold DL; Bar-Or A; Cree BAC; Cross AH; Kubala Havrdova E; Kappos L; Stuve O; Wiendl H; Wolinsky JS; Dahlke F; et al. (The Lancet. Neurology, 2024)